CREDIT AGREEMENT dated as of May 25, 2020 among REGENERON PHARMACEUTICALS, INC. The Lenders Party Hereto GOLDMAN SACHS BANK USA as Administrative Agent GOLDMAN SACHS BANK USA as Sole Bookrunner and Sole Lead ArrangerCredit Agreement • May 29th, 2020 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
CREDIT AGREEMENT (this “Agreement”) dated as of May 25, 2020 among REGENERON PHARMACEUTICALS, INC., a New York corporation, the LENDERS from time to time party hereto and GOLDMAN SACHS BANK USA, as Administrative Agent.
UNDERWRITING AGREEMENTUnderwriting Agreement • May 29th, 2020 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Regeneron Pharmaceuticals, Inc., a corporation organized under the laws of New York (the “Company”), Sanofi, a French société anonyme (“Sanofi”), and Aventisub LLC, a Delaware limited liability company and wholly owned subsidiary of Sanofi (“Aventisub” and together with Sanofi, the “Selling Shareholders”), confirm their respective agreements with the several underwriters named in Schedule A hereto, acting severally and not jointly (the “Underwriters”), for whom you (in such capacity, the “Representatives”) are acting as representatives, with respect to (i) the sale by the Selling Shareholders of an aggregate of 11,831,496 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) and the purchase by the Underwriters, acting severally and not jointly, of the respective number of shares of Common Stock set forth on Schedule A hereto, and (ii) the grant by the Selling Shareholders, to the Underwriters, acting severally and not jointly, of the option described
STOCK REPURCHASE AGREEMENT BY AND BETWEEN REGENERON PHARMACEUTICALS, INC., AND SANOFI Dated as of May 25, 2020 STOCK REPURCHASE AGREEMENTStock Repurchase Agreement • May 29th, 2020 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 25, 2020 by and between Regeneron Pharmaceuticals, Inc., a New York corporation (“Regeneron”) and Sanofi, a company organized under the laws of France (“Sanofi” or the “Selling Shareholder”).
Regeneron Pharmaceuticals, Inc. Tarrytown, New York 10591 May 25, 2020Regeneron Pharmaceuticals, Inc. • May 29th, 2020 • Pharmaceutical preparations
Reference is made to the Amended and Restated Investor Agreement (as may be amended from time to time, the “Investor Agreement”), dated as of January 11, 2014, by and among Sanofi, a company organized under the laws of France (“Sanofi”), sanofi-aventis US LLC, a Delaware limited liability company (“Sanofi US”), Aventisub LLC, a Delaware limited liability company (formerly Aventis Pharmaceuticals Inc., a Delaware corporation) (“Aventis”), sanofi-aventis Amérique du Nord, a société en nom collectif organized under the laws of France (the “Investor”, which was merged with Sanofi on October 30, 2018, and, together with Sanofi, Sanofi US and Aventis, the “Purchaser Parties”), and Regeneron Pharmaceuticals, Inc., a New York corporation (“Regeneron”), as amended pursuant to that certain letter agreement, dated as of January 7, 2018, by and among Regeneron and the affiliates of the Purchaser Parties party thereto (the “2018 Letter Agreement”). Capitalized terms that are used but not defined he
